Pioneering GIP
receptor antagonism for obesity treatment

We’re addressing obesity and overweight through GIP receptor antagonism, developing treatments that go beyond weight loss to deliver long-term sustained health, without compromising on tolerability.

AT-7687

AT-7687 is Antag’s GIPR antagonist – a peptide drug designed not just as a stand-alone product but also as a flexible therapeutic agent that can be used in combination with existing anti-obesity medications and emergent treatments of obesity.

AT-7687 is engineered to target and deactivate the GIPR pathway, which, when dysregulated, contributes to fat storage, insulin resistance, and metabolic dysfunction.

Developments to date highlight several key advantages of AT-7687 vs. the current standard of care, positioning it to address a broader range of patients’ unmet needs and treatment options as evidenced by our preclinical/clinical studies:

  • Differentiated mechanism of action involving mechanisms independent of appetite suppression.
  • High-quality weight loss accompanied by favourable changes across multiple biomarkers and improvements in body composition associated with cardiometabolic health.
  • Excellent safety and tolerability profile, with no gastrointestinal-related side effects and no need for dose titration.
  • Pharmacokinetic profile suitable for once-weekly administration.
  • High potency, with multi-organ target engagement observed at the lowest tested clinical doses.

Furthermore, AT-7687 demonstrates straightforward and versatile formulation properties and is uniquely positioned to develop as a monotherapy or as a co-formulation with GLP-1RAs and other emerging obesity medications (e.g., amylins).